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Preclinical drug discrimination studies of the synthetic cathinone, 4-methylmethcathinone
(mephedrone) have demonstrated its effects are comparable to those of other popular
psychostimulant drugs. Few studies have directly examined the contribution of specific
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investigated the role of dopamine and serotonin receptors in these effects. Eight adult male
Sprague-Dawley rats were trained to discriminate 3.0 mg/kg mephedrone from saline. After
dose-response curves were determined with mephedrone (0.375-3.0 mg/kg), a series of stimulus
antagonism tests were conducted with dopamine antagonists (Sch 23390, haloperidol) and
serotonin antagonists (WAY 100,635, MDL 100,907, pirenperone) administered as a
pretreatment with each mephedrone dose. Attenuation of mephedrone discrimination by Sch
23390 and haloperidol implicates the involvement of both D1 and D2 dopamine receptors in these
effects. Partial attenuation of discrimination by MDL 100,907 and pirenperone, but not WAY
100,635, indicates 5HT2 receptors also contribute to these effects, while 5HT1A receptors do not.
The absence of full stimulus antagonism with these compounds
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discriminative stimulus effects may be mediated by a combination of monoamine receptors or
other neurotransmitter actions yet to be evaluated. These results contribute to a growing body of
literature regarding the interoceptive stimulus effects of mephedrone and serve to inform clinical
science regarding the neurochemical mechanisms involved with abuse risks of this substance.
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INTRODUCTION
Synthetic cathinones are common constituents of the psychoactive ba
emerged on the clandestine drug market in the United S a e a d E
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alternative to traditional psychostimulant drugs (Goodnough & Zezima, 2011; Winstock &
Ramsey, 2010). These substances are structurally similar to the psychoactive ingredient in Catha
edulis (Khat), a plant widely consumed primarily in parts of Africa and the southern Arabian
peninsula (Sheikh et al., 2014). Because of its association with a myriad of negative health
outcomes, from dependence to increased risk of heart attack and stroke, khat is listed as a
prohibited substance by the United Nations, as well as outlawed in many countries, including the
United States, Canada, and the United Kingdom (Sheikh et al., 2014).
While synthetic cathinones share a similar molecular structure to cathinone, synthetic
cathinones such as mephedrone (4-methylmethcathinone, 4-MMC), and 3-4
methylenedioxypyrovalerone (MDPV) are significantly more potent (Gregg et al., 2015).
Moreover, mephedrone a d MDPV a e

c ea

d

d

a e ed a ecstasy

e (Gregg et al., 2015). Medical professionals noted a disturbing trend of
severe adverse effects linked to mephedrone, and as a result, in 2014 the United States Drug
Enforcement Administration permanently added this substance along with several other synthetic
cathinones to the Schedule I list of controlled substances (Drug Enforcement Administration,
2014b; Gibbons & Zloh, 2010; Kasick et al., 2012; Rosenbaum et al., 2012).
Despite attempts to curtail their recreational use through legal restrictions and education,
use of synthetic cathinones remains a public health concern (German et al., 2014). The Drug
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(NFLIS) special report on synthetic cannabinoids and synthetic cathinones indicates synthetic
cathinone use continues to increase; reports of use nearly doubled from 29,648 in the 2010-2013
reporting period to 51,824 in the 2013-2015 reporting period (Drug Enforcement Administration,
2011, 2014a, 2016). According to the DEA, mephedrone was the most prevalent synthetic
cathinone detected in samples seized by law enforcement and submitted to federal, state, and
local laboratories participating in the National Forensic Laboratories Information System
(NFLIS) in the United States from 2010-2013, and remains among the 20 most commonly
reported synthetic cathinones found in samples according to the most recent report (Drug
Enforcement Administration, 2014a, 2016).
Scientific research on the psychopharmacology of synthetic cathinones has expanded
considerably in recent years, no doubt due to their continued prevalence as recreational drugs of
abuse. Several published preclinical studies indicate that the common constituents found in bath
salts are comparable in abuse liability and pharmacology to other abused stimulants, such as
MDMA, cocaine, or amphetamines (Baumann et al., 2012; Berquist et al., 2017; Cameron et al.,
2013; Harvey et al., 2017). Furthermore, the chemical structure of mephedrone resembles
prototypical phenylethylamine derivatives, such as MDMA and methamphetamine, and therefore
may serve as a useful model for predicting the effects of emerging synthetic cathinones that
share a similar structure (Berquist et al., 2017). Among these similar second generation synthetic
cathinones, 4-methyl-N-ethylcathinone (4-MEC) a d 4 - methyl- -pyrrolidinopropiophenone (4MePPP) can already be found alongside mephedrone in the 20 most commonly identified
synthetic cathinones in samples submitted to NFLIS laboratories (Drug Enforcement
Administration, 2014a).
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Neurochemical studies indicate mephedrone is a nonselective substrate for release at
dopamine, serotonin, and norepinephrine transporters (DAT, SERT, & NET respectively),
similar to the actions of MDMA (Baumann et al., 2012). When administered intravenously,
mephedrone increases extracellular serotonin (5-HT), dopamine (DA), and norepinephrine (NE),
with a greater effect on 5-HT release (Baumann et al., 2012; Kehr et al., 2011). Additionally,
mephedrone is a 5-HT and DA transport inhibitor, with higher affinity for DAT than SERT
(Hadlock et al., 2011; Martínez-Clemente et al., 2012). Similar to more traditional psychomotor
stimulants, mephedrone produces spontaneous increases in locomotor activity, produces
conditioned place preference in rats and mice equal to or greater than that produced by
amphetamine at doses as low as 5 mg/kg, and it is readily intravenously self-administered by
both male and female rats, consistent with its high abuse liability (Creehan et al., 2015; Huang et
al., 2012; Karlsson et al., 2014; Lisek et al., 2012; Motbey et al., 2013; Nguyen et al., 2016).
Drug discrimination has long been regarded a

d a da d paradigm for predicting

abuse-related behavioral effects of psychoactive drugs. Several meta-analyses indicate this
paradigm is among the best predictors of scheduling risk, particularly when drugs with known
abuse potential are tested for substitution with subjects trained to discriminate the novel
compound (Horton et al., 2013; Huskinson et al., 2015). This well-established in vivo preclinical
behavioral paradigm has also been demonstrated to have exceptional predictive utility for
discerning neurochemical mechanisms of drug action (Glennon & Young, 2011). At the time this
study was initiated, seven published studies evaluated the discriminative stimulus effects of
mephedrone (4-MMC) in rodents (Berquist et al., 2017; DeLarge et al., 2017; Erwin et al., 2019;
Gatch et al., 2013; Harvey & Baker, 2016; Saber et al., 2019; Varner et al., 2013). Five of these
studies utilized mephedrone as the training stimulus. Collectively, these studies characterized the
3

interoceptive stimulus effects of mephedrone through tests of stimulus substitution, potentiation,
and antagonism. These findings are summarized in Table 1 and Table 2.

Table 1. Preclinical Findings with Mephedrone: Drug Discrimination Substitution Tests

Table summarizing the substitution tests from published drug discrimination studies using rats trained to discriminate
mephedrone from saline (Berquist et al., 2017; DeLarge et al., 2017; Erwin et al., 2019; Saber et al., 2019; Varner et al., 2013).
* indicates substitution was dependent on the mephedrone training dose.

Table 2. Preclinical Findings with Mephedrone: Drug Discrimination Antagonism and
Transport Inhibitor Tests

Table summarizing the antagonism and transport inhibitor tests from published drug discrimination studies using rats trained to
discriminate mephedrone from saline (DeLarge et al., 2017; Erwin et al., 2019; Saber et al., 2019; Varner et al., 2013).
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Of the myriad of drugs tested for substitution in rodents trained to discriminate
mephedrone, substances with predominantly dopaminergic actions (e.g., amphetamine,
methamphetamine) or a mixture of serotonergic and dopaminergic actions (MDMA, MDA)
consistently substituted for mephedrone, while drugs with predominantly serotonergic actions
(e.g., LSD, fenfluramine) produced only partial substitution (Berquist et al., 2017; DeLarge et
al., 2017; Erwin et al., 2019; Saber et al., 2019; Varner et al., 2013). Opioids (morphine, heroin),
dissociative anesthetics (ketamine, phencyclidine) and delta-9-THC also produced only partial
substitution for mephedrone (Berquist et al., 2017; DeLarge et al., 2017; Erwin et al., 2019;
Saber et al., 2019; Varner et al., 2013). Of particular interest, the extent of substitution with
psychostimulants (cocaine, (+)-methamphetamine, d-amphetamine) is dependent on the
mephedrone training dose, with full substitution observed for low training doses and minimal or
partial substitution for high training doses (Berquist et al., 2017; Saber et al., 2019) The sigma
receptor antagonist rimcazole and the norepinephrine transport (NET) inhibitor desipramine
potentiated the effects of mephedrone, whereas the serotonin transport (SERT) inhibitor,
fluoxetine blocked mephedrone discrimination at low doses and potentiated its effects at high
doses (DeLarge et al., 2017).
In drug discrimination assessments with antagonists, the D1 antagonist SCH23390
produced marked decrease in response rates, but blocked the discriminative stimulus effects of
mephedrone in the subjects that responded, while the D2 agonist sulpiride produced partial
antagonism in rats that were trained on a low (0.5mg/kg) dose of mephedrone (Saber et al.,
2019). Haloperidol, a D2 antagonist, SB242084, a 5-HT2c antagonist, and 5-HT2a/2c antagonists
ketanserin and ritanserin all failed to block the discrimination of mephedrone (Erwin et al., 2019;
Saber et al., 2019; Varner et al., 2013). Considered together, these studies indicate that the
5

discriminative stimulus effects of mephedrone may be partially mediated by both dopaminergic
and serotonergic receptor activities.
The aim of the present study was to replicate and expand on previous investigations of
mephedrone stimulus antagonism. Two dopamine antagonists (Sch 23390, haloperidol) and three
serotonin antagonists (MDL 100, 907, pirenperone, WAY 100,635) were each assessed in rats
trained to discriminate 3 mg/kg mephedrone.
METHODS
Subjects
Eight adult male Sprague-Dawley rats (380g-450g) served as subjects. Rats were
individually housed in polycarbonate cages with corncob bedding (Teklad, #7097, Envigo,
Madison, Wisconsin, USA). The animal facilities were maintained at 22C +/- 2, and humidity
50% +/- 5, with a 12:12 light:dark cycle (lights on at 6/7 depending on daylight savings time).
Subjects were maintained at 90% of their average free feed weights and had ad libitum access to
water. All procedures were reviewed and approved by the Western Michigan University
Institutional Animal Care and Use Committee and were in accordance with the guidelines of the
Guide for the Care and Use of Laboratory Animals (National Research Council of the National
Academies, 2011) and EU Directive 2010/63/EU.
Apparatus
All training and test sessions were conducted utilizing eight sound-attenuated operant
conditioning chambers (ENV-001, Med Associates Inc., St. Albans, Vermont, USA), and
controlled using Med-PC software (version IV, Med Associates Inc.). Each chamber was
equipped with a 28 Volt house light, a ventilation fan, three retractable levers approximately two
inches from the floor, and a single stimulus light directly above each the right and left levers.
Reinforcement during training sessions consisted of 45 mg Dustless Precision Pellets®
6

(Product# F0021, Bio-Serv Inc., Flemington, New Jersey, USA) dispensed from a pellet
dispenser directly above the center lever. Neither of the stimulus lights were active during
training or test sessions.
Drugs
(±)-Mephedrone-hydrochloride (4-MMC) was provided by the National Institute on Drug
Abuse Drug Control Supply Program (Bethesda, MD, USA). (R)-(+)-a-(2,3-Dimethoxyphenyl)1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol (MDL 100,907) and N-[2-[4-(2Methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclohexanecarboxamide trihydrochloride
(WAY 100,635) were provided by the National Institutes of Mental Health Chemical Synthesis
and Drug Supply Program. R(+)-7-Chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H3-benzazepine hydrochloride (SCH 23390), 3-[2-[4-[(4-fluorophenyl)-oxomethyl]-1piperidinyl]ethyl]-2-methyl-4-pyrido[1,2-a]pyrimidinone (pirenperone) and haloperidol were
purchased from Sigma Chemical Company, Inc. (St. Louis, MO, USA). Haloperidol was first
dissolved in a few drops of 0.1 M HCl and diluted in sterile water. Pirenperone was dissolved in
30% 2-hydroxypropyl-beta-cyclodextrin at a concentration of 1 mg/ml and diluted with sterile
water. MDL 100,907 was dissolved with a few drops of glacial acetic acid and diluted with
sterile water. All other drugs were dissolved in bacteriostatic 0.9% sodium chloride. Drug doses
were calculated based on the weights of solid compound and were administered via
intraperitoneal (ip) injections at a constant volume of 1 ml/kg body weight. Mephedrone was
administered 15 minutes prior to behavioral testing. SCH 23390 was administered 15 minutes
before the mephedrone, 30 minutes prior to testing. All other antagonists were administered 45
minutes prior to mephedrone, 60 minutes before behavioral testing.
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Procedures
Preliminary Training: Training began with a single 60-minute session, during which no
levers were extended, and pellets were delivered on a 60 second fixed time interval, in order to
acquaint subjects with the location and sounds of the pellet dispenser. Additionally, after this
first session rats were given a supplement of approximately ten precision dustless pellets in their
home cages to decrease their novelty and ensure the rats would consume them in subsequent
sessions. All following training sessions were 20 minutes in duration and were conducted 5-6
days a week. Preliminary lever training began with only the center lever present, whereby
reinforcement was delivered on a fixed ratio 1 (FR 1) schedule that was gradually incremented to
a FR 20 schedule across 10-15 daily sessions.
Errorless Training: When responding was stable on an FR 20 schedule, errorless training
commenced. During this phase, rats received an intraperitoneal injection of either saline (S) or
3.0 mg/kg mephedrone (D) 15 minutes prior to the start of each session. Rats again were placed
on a FR1 schedule that was incremented across four to nine sessions to FR 20. Subjects 1-4
received reinforcement for completing the FR requirement on the right lever following drug
injections and the left lever following saline vehicle (V) injections. Conditions were reversed for
subjects 5-8.
Discrimination Training: Once reliably responding at an FR20 in the errorless phase,
discrimination training commenced. Both errorless training and discrimination training were
conducted using the following 12-day pattern: VVDDVDVVDDVD. During discrimination
training, both the left and right lever were extended. Completion of the FR on the injectionappropriate lever was reinforced and responses on the other lever reset the response requirement.
Criteria for discrimination was set at 80% correct lever responding for eight out of ten
8

consecutive training sessions. Once the aforementioned discrimination criteria were met, subjects
commenced testing.
Testing Phase: Substitution tests were initially conducted with a range of mephedrone
doses (0.375, 0.75, 1.5, 3 mg/kg) and saline to generate a dose response curve. Subsequently,
antagonist tests were conducted with a single dose of each antagonist (indicated below) with
each of the aforementioned mephedrone doses. Test sessions were conducted in a similar manner
to training sessions with the exception that no reinforcers were delivered, and sessions
terminated upon completion of the first FR on either lever, or after 20 minutes, whichever came
first. Between tests, subjects were required to meet criteria for stimulus control on at least one V
and D training session. Antagonists were injected 30 minutes (0.03 mg/kg Sch 23390) or 60
minutes (0.25 mg/kg haloperidol, 0.32 mg/kg pirenperone, 1.6 mg/kg WAY 100,635, 0.1 mg/kg
MDL 100,907) prior to each test session followed by one of the aforementioned mephedrone
doses 15 min before each test session.
Data Analysis
Sessions to criteria was determined from the first session where both levers were
available. Percent drug lever selection was determined by dividing the number of responses
emitted on the mephedrone-paired lever by the total number of responses emitted on both levers
and multiplying by 100. Response rates were expressed as the number of responses per second
during the test session. Subjects that failed to complete 10 total lever presses within the 20-min
test session were not considered in the calculation of percent mephedrone-lever selection
however were included in the statistical analysis of response rates. Mean percent of drug lever
responding and mean response rate for each dose and combination were determined and plotted
for visual analysis.
9

During initial mephedrone testing to establish the dose-response curve, full substitution
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mephedrone-lever selection, less than 20% mephedrone lever responding was considered full
antagonism, and partial attenuation was considered anywhere between 20%-79% drug lever
responding. For each antagonist assessed, the response rate was statistically analyzed with a twoway repeated-measures analysis of variance (RM ANOVA) with antagonist pre-treatment and
mephedrone dose as the two independent variables. Statistical significance was determined at
alpha of p <0.05. A Holm-Sidak multiple comparison test was conducted following the RM
ANOVA. All statistical and graphical analyses were performed using the GraphPad Prism
version 7 software (GraphPad Software, Inc., La Jolla, CA, USA).
RESULTS
All eight rats met the discrimination criteria within an average of 29.8 (± 5.9) training
sessions (Range:18-62). Mephedrone produced dose-dependent increase in drug-lever responses
with full substitution at 1.5 mg/kg and 3.0mg/kg mephedrone. Response rate was reduced by 3.0
mg/kg mephedrone compared to saline and lower mephedrone doses, but differences were not
statistically significant.
Dose response curves for mephedrone alone and with each antagonist pre-treatment are
displayed in figure 1. The D1 receptor antagonist, Sch 23390 (0.03 mg/kg) attenuated
discrimination of mephedrone at 0.375mg/kg, 0.75mg/kg, and 1.5mg/kg, but failed to block
discrimination of the training dose. This antagonist also produced a significant decrease in
response rate. A two way RM ANOVA on response rate indicated a statistically significant effect
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of pre-treatment with Sch 23390 (F(1,4)=23.29, p=0.01) but no significant effect of mephedrone
dose. The D2 receptor antagonist, haloperidol (0.25 mg/kg) partially attenuated mephedrone
discrimination at 1.5 and 3.0 mg/kg. Haloperidol appeared to produce a decrease in response
rate, and completely eliminated responding in two animals, however a two way RM ANOVA
determined that there was no statistically significant effect of pre-treatment F(1,5)=6.06,
p=0.06), nor was there an effect of mephedrone dose.

Figure 1. Pretreatment with Dopamine and Serotonin Antagonists in Male Rats
Both Sch 23390 and haloperidol attenuated discrimination of low MEPH doses, but disrupted responding in at least half the
animals, precluding statistical analysis. The 5-HT2 antagonists, pirenperone and MDL produced a rightward shift in the MEPH
dose response curve, whereas the 5-HT1A antagonist, WAY 100,635 did not alter MEPH discrimination.
(4-MMC, N=8; Sch 23390, N=6-7; Hal, N=3-4; Piren, N=5-7; WAY, N=7-8; MDL, N=5)

The 5-HT1A antagonist, WAY 100635 (1.6 mg/kg) failed to block discrimination of
mephedrone at any dose. Of the seven rats to complete testing, WAY 100635 completely
11

blocked discrimination in one, partially blocked in another, and failed to block in the remaining
five animals. Of interest, WAY 100,635 appeared to potentiate low doses of mephedrone; when
administered with 0.375 mg/kg mephedrone, drug lever responding increased (X=41.9%)
compared to the 0.375 dose of mephedrone alone (X=21.6%). When tested with 0.375 mg/kg
mephedrone alone, only one animal responded exclusively on the drug lever. In comparison, pretreatment with WAY 100,635 prior to 0.375mg/kg mephedrone produced full substitution in
three animals (96.6%, 100%, 92%).
The 5-HT2A antagonist, MDL 100,907 (0.1 mg/kg) and the less selective 5-HT2
antagonist, pirenperone (0.32mg/kg) produced partial attenuation of mephedrone discrimination
and produced a rightward shift in the mephedrone dose response curve. Although pre-treatment
with these antagonists suppressed response rate compared to the effects of mephedrone alone,
these effects were not statistically significant. A two way RM ANOVA on response rate
following antagonism pretreatments revealed no main effect of WAY100,635 pretreatment
[F(1,7)=4.427, p=0.07]), MDL100,907 pretreatment [F(1,3)=4.546, p>0.1], or pirenperone
pretreatment [F(1,4)=0.5972, p=0.4828], as well as no significant effect of mephedrone dose or
dose by pre-treatment interaction.
DISCUSSION
The present study examined the contribution of serotonergic and dopaminergic
mechanisms to the discriminative stimulus effects of mephedrone through antagonism testing in
rats trained to discriminate this synthetic cathinone from saline. Although stimulus control was
established in all eight rats, the number of sessions required to meet criteria was variable. Five of
the subjects achieved criteria for stimulus control in 18-19 sessions, while the remaining three
required 40, 44, or 62 sessions to meet these criteria. This disparity may indicate differing levels
12

of sensitivity to mephedrone, though other methodological variables related to training cannot be
ruled out. Nonetheless, the number of training sessions required to establish stimulus control in
the current study were comparable to that reported in previous mephedrone drug discrimination
studies despite a number of methodological differences including rodent strain and training
methods (DeLarge et al., 2017; Erwin et al., 2019; Saber et al., 2019; Varner et al., 2013).
A limited number of published studies have evaluated the effects of dopamine antagonists
on mephedrone discrimination. Saber et al. (2019) reported partial attenuation of mephedrone
discrimination with the D2 antagonist, sulpiride. Consistent with those findings, the current study
found partial attenuation of mephedrone discrimination by Sch 23390 and haloperidol. These
findings implicate the involvement of D1 and D2 dopamine receptor activities in the interoceptive
effects of mephedrone. However, the lack of full stimulus antagonism suggests other receptor
mechanisms may also contribute to these effects. Whereas these DA antagonists also
substantially suppressed responding, their effects on mephedrone discrimination should be
interpreted with caution. The 5-HT2 antagonists MDL 100,907 and pirenperone also partially
attenuated mephedrone discrimination with less overall disruption of response rate. Failure of
WAY 100, 635 to alter mephedrone discrimination suggest 5-HT1A receptors do not contribute to
these effects. These findings suggest that the discriminative stimulus effects of mephedrone rely
a combination of dopaminergic and serotonergic mechanisms. This conclusion is supported by
neurochemical analyses which found that mephedrone administration increases extracellular
levels of dopamine and serotonin, as well as the transporter-mediated release of monoamines
(Baumann et al., 2012; Hadlock et al., 2011).
The current findings showing partial antagonism with MDL100,907 and pirenperone are
generally consistent with previously published results indicating 5-HT2A/C antagonists, ritanserin
13

and ketanserin, as well as 5-HT2C antagonist, SB242084 all failed to attenuate mephedrone
discrimination (Erwin et al., 2019; Saber et al., 2019). Interestingly, in the present study WAY
100, 635 appeared to potentiate the lowest dose of mephedrone (0.375mg/kg). Previous research
has established that a low dose (1 mg/kg) of the serotonin reuptake inhibitor, fluoxetine, blocked
mephedrone discrimination, while a higher dose (5.6 mg/kg) potentiated mephedrone
discrimination (DeLarge et al., 2017). Other neurochemical mechanisms examined in previous
studies include glutamatergic and noradrenergic receptor-mediated effects. For example the
sigma receptor antagonist rimcazole and the NET inhibitor desipramine were found to potentiate
mephedrone (DeLarge et al., 2017). These findings are supported by neurochemical analyses
demonstrating substrate activity at 5HT , DA, and NE transporters, while repeated administration
of mephedrone produces serotonergic deficits, with no corresponding dopaminergic deficits
(Baumann et al., 2012; Hadlock et al., 2011). Considered together, these data suggest that
monoamine transporter reuptake inhibition may also play a role in the pharmacological
mechanisms underlying the discriminative stimulus effects of mephedrone.
Methodological differences between the current study and previous studies are worth
noting. Three of the five aforementioned mephedrone drug discrimination studies utilized
cumulative dosing to establish the dose-effect curve (DeLarge et al., 2017; Erwin et al., 2019;
Varner et al., 2013). While this method decreases the number of sessions required to produce a
dose response curve, it also has been shown to produce quantitative differences from traditional
testing and thus may explain disparate results between studies (Thompson et al., 1983). Despite
this methodological difference, the results of the present study are generally consistent with other
mephedrone discrimination studies that evaluated dopamine and serotonin antagonists.
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Another methodological difference between the current study and the previous
mephedrone discrimination studies is the use of reinforced test sessions. Aside from Berquist et
al. (2017), all of the previous mephedrone discrimination research utilized reinforced test
sessions, in which either lever produced reinforcement upon the completion of an FR. This could
influence discrimination of the interoceptive effects of mephedrone, though a comprehensive
literature review suggests that the drug discrimination assay is robust enough to be unaffected by
differences in testing strategies such as reinforced test sessions (Gauvin et al., 2016).
The non-significant reduction in response rates by mephedrone observed in the present
study fails to clarify the literature with regard to effects of mephedrone on response rate. Of the
five published studies using mephedrone as the training drug, two indicated either no rate
reduction or a non-significant rate reduction by mephedrone alone (Berquist et al., 2017; Saber et
al., 2019). The remaining three studies reported significant abolishing effects of mephedrone in a
dose-dependent fashion (Erwin et al., 2019; Saber et al., 2019; Varner et al., 2013). This
difference in effect on response rates could be the result of the dose used, or the training method
used to reach the final training dose. The present study and that by Berquist et al.,(2017) began
training at the terminal dose (1.0mg/kg or 3.0mg/kg) in contrast to other studies in which the
training dose was gradually incremented from 0.5mg/kg until subjects acquired the
discrimination or the terminal dose of 3.2mg/kg was obtained (DeLarge et al., 2017; Erwin et al.,
2019; Saber et al., 2019; Varner et al., 2013). In a second experiment Saber et al., (2019)
implemented a fading procedure by training subjects to discriminate 3.2 mg/kg and gradually
reduced the training dose to 0.5 mg/kg. It is unclear whether these differences in training
methods led to more sensitive discrimination, or increased sensitivity to the rate decreasing effect
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of mephedrone. Direct comparisons between mephedrone dosing methods specifically are
necessary to elucidate these differences.
In summary, the results described herein provide further empirical support for the partial
role of dopamine and serotonin receptors in the discriminative stimulus effects of mephedrone.
These data contribute to a growing body of literature regarding the interoceptive stimulus effects
of mephedrone and serve to inform clinical science regarding the neurochemical mechanisms
involved with abuse risks of this substance. Additional research is necessary to clarify the
neurochemical actions underlying the stimulus effects of mephedrone, which are still not well
understood. Specifically, the role of NET, SERT, sigma receptors and the combination of
dopamine and serotonin receptors should be further evaluated. Moreover, replications with
female subjects are called for, as to date there are no published drug discrimination studies
utilizing female rats trained to discriminate mephedrone.
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